Adaptive Biotechnologies Reports Third-Quarter Revenue of $83.9M

Third-quarter 2026 revenue fell 10.7% year over year from $94M. Net income attributable to the company was $2.9M, compared with $9.5M a year earlier. MRD revenue growth was partly offset by the end of its Genentech collaboration.